Does Blue Cross Blue Shield Cover Farxiga?
The verdict
Covered on most plans
Yes — Blue Cross Blue Shield plans cover Farxiga for its on-label indications (type 2 diabetes, heart failure, chronic kidney disease) across commercial, ACA, Medicare, and Medicaid. MMIT data (as of Sept 11, 2025) shows 92.1% commercial, 96.6% ACA, 95.1% Medicare, and 99.8% Medicaid coverage nationally. BCBS is a federation of 30-plus independent regional affiliates, so tier and step-therapy rules vary by your specific Blue plan. The key commercial nuance: Farxiga has the highest step-therapy rate in this drug class — 45.8% of commercial plans require metformin first — so many Blue commercial plans have a step to clear before Farxiga is approved.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield using your member ID.
Key facts
Farxiga has the highest commercial step-therapy rate in its drug class: 45.8% of commercial plans require metformin-first step therapy before approving it (MMIT, as of Sept 11, 2025).
MMIT via GoodRx (as of Sept 11, 2025)
The 2026 IRA negotiated Maximum Fair Price for Farxiga is $178.50 per 30-day supply — a 68% reduction from the prior list price of approximately $556.
CMS Medicare Drug Price Negotiation Program, 2026 MFP
Generic dapagliflozin (the active ingredient in Farxiga) is now FDA-approved and available — a potential lower-cost option on BCBS formularies.
FDA Drug Approvals and Databases
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield covers Farxiga depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Farxiga is covered on Blue Cross Blue Shield Medicare Part D plans. Prior authorization and step therapy are essentially nil for Farxiga on Medicare — nationally only 0.2% of Part D plans require PA and 0.3% require step therapy (MMIT, as of Sept 11, 2025). As Part D sponsors, Blue Medicare plans are required to carry Farxiga at the IRA negotiated Maximum Fair Price of $178.50 per 30-day supply, effective January 1, 2026 (a 68% reduction from the prior list price of approximately $556). AstraZeneca's own data reports an average Medicare Part D out-of-pocket for Farxiga of approximately $38.82 per month (manufacturer-reported, not a guarantee). The $2,100 annual out-of-pocket cap (CMS 2026 Part D redesign) limits worst-case exposure. Medicare beneficiaries cannot use any commercial copay card.
Commercial / Employer
Group & marketplace plans
Farxiga is covered across Blue Cross Blue Shield commercial and ACA plans for its on-label indications. Nationally, 92.1% of commercial plans and 96.6% of ACA plans cover Farxiga (MMIT, Sept 11, 2025) — slightly lower than other SGLT2s because step-therapy utilization management is very high. Farxiga carries the heaviest commercial step-therapy rate of any drug in this batch: 45.8% of commercial plans require metformin-first step therapy (MMIT, Sept 11, 2025), and PA is required in 17.1% of commercial plans. This means many Blue commercial plans will need documentation of a prior metformin trial before approving Farxiga. ACA plans show 23.6% step therapy. BCBS is a federation — the exact step requirements, PA criteria, and tier placement vary by affiliate and PBM. Route to your member ID card to identify your specific Blue affiliate. Medicaid plans affiliated with BCBS cover Farxiga at 99.8% (MMIT); step therapy is common (30.6% PA, 25.4% step). Generic dapagliflozin is now FDA-approved and available — verify whether your plan covers it at a lower tier as an alternative. AstraZeneca's average commercial copay for Farxiga is approximately $26 (manufacturer-reported, not a guarantee).
The 4 boxes you must tick to get approved
Commercial plans that will consider Farxiga require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Farxiga actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $400–$600+ per 30-day supply at retail pharmacy for the brand (Farxiga; pharmacy-variable estimate). Generic dapagliflozin is available at lower cost — verify price at your pharmacy.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: IRA Maximum Fair Price $178.50 per 30-day supply effective January 1, 2026; $2,100 annual out-of-pocket cap in 2026; AstraZeneca average Part D OOP ~$38.82/month (manufacturer-reported, not a guarantee). Commercial/ACA: AstraZeneca average commercial copay ~$26 (manufacturer-reported, not a guarantee); tier and cost-share vary by Blue affiliate. All figures are estimates — confirm with your specific Blue plan.
Typical monthly copay once prior authorization is approved.
All dollar figures are estimates and vary by Blue affiliate, PBM, plan tier, and benefit phase. Identify your specific BCBS affiliate from your member ID card, then look up Farxiga on that plan's drug list. Consider whether generic dapagliflozin — now available — could be a lower-cost option on your plan formulary. AstraZeneca dollar figures are manufacturer-reported averages and are not a guarantee of your specific cost. Medicare beneficiaries cannot use manufacturer commercial copay cards.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your specific Blue affiliate from your member ID card
Blue Cross Blue Shield is a federation of more than 30 independent regional affiliates. Your member card names your specific Blue plan (Anthem, Florida Blue, HCSC, Highmark, CareFirst, etc.). Go to that affiliate's website to search the drug formulary for Farxiga — national BCBS data does not uniformly apply across affiliates.
- 2
Check step-therapy requirements on your plan formulary
Because 45.8% of commercial plans nationally require metformin-first step therapy for Farxiga, look for a step-therapy or prior-authorization flag on your plan's formulary tool. If a step is required, your prescriber can submit documentation of your metformin history or clinical reason metformin was not appropriate. Also check whether your plan covers generic dapagliflozin at a lower tier.
- 3
Call member services or your pharmacist to confirm 2026 cost-share
Call the member services number on the back of your Blue ID card. Ask: (1) What tier is Farxiga on my 2026 plan? (2) Is a step therapy or PA required? (3) Does my plan cover generic dapagliflozin at a lower tier? (4) What will I pay per fill after my deductible? Your pharmacist can also run a real-time eligibility check.
Options if Blue Cross Blue Shield won't cover Farxiga
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Generic dapagliflozin (Farxiga generic)
FDA-approved generic dapagliflozin is now available and may carry lower cost-share on BCBS formularies than the brand Farxiga. Verify tier and pricing on your specific Blue plan's drug list.
Jardiance (empagliflozin)
Another SGLT2 inhibitor for T2D, heart failure, and CKD; no generic yet. Covered on most BCBS plans. The 2026 IRA negotiated price for Jardiance is $197 per 30-day supply. Discuss with your prescriber.
Metformin (generic)
First-line generic diabetes medication; Tier 1 on virtually all formularies at approximately $4/month. Required as a prior step on many commercial plans before Farxiga approval.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes — BCBS covers Farxiga for type 2 diabetes, heart failure, and CKD across commercial, ACA, Medicare, and Medicaid. Nationally, 92.1% of commercial plans and 95.1% of Medicare plans cover Farxiga (MMIT, Sept 11, 2025). The important caveat: 45.8% of commercial plans require a metformin-first step before approving Farxiga. Identify your specific Blue affiliate from your member ID card and check the formulary to confirm tier and any step requirement.
Farxiga carries the highest commercial step-therapy rate in its drug class — 45.8% of commercial plans nationally require a metformin-first step (MMIT, Sept 11, 2025). This reflects payer utilization management: metformin is a low-cost, well-established first-line diabetes drug. BCBS affiliates that use this step require documentation that metformin was tried at adequate doses or is contraindicated. On Medicare, step therapy is near-nil (0.3%); the step is a commercial and Medicaid phenomenon.
Generic dapagliflozin is FDA-approved and available. Many BCBS plans will add it to their formularies at a lower tier than the brand Farxiga, potentially reducing your cost-share. Not all BCBS affiliates have updated their 2026 formularies uniformly — verify whether generic dapagliflozin is covered on your specific Blue plan and at what tier. Ask your pharmacist or check the formulary tool on your affiliate's website.
CMS negotiated a Farxiga Maximum Fair Price of $178.50 per 30-day supply, effective January 1, 2026 — a 68% reduction from the prior list price of approximately $556. All BCBS Medicare Part D plans must apply this price as a ceiling. AstraZeneca reports an average Medicare out-of-pocket of approximately $38.82 per month (manufacturer-reported, not a guarantee). The $2,100 annual Part D out-of-pocket cap also applies in 2026.
PA is essentially not required for Farxiga on Medicare Part D — only 0.2% of Medicare plans require it nationally (MMIT, Sept 11, 2025). On BCBS commercial plans, PA is required in 17.1% of plans nationally, and 45.8% require a metformin-first step. Medicaid affiliated plans require PA in 30.6% of cases. Verify the specific requirement on your Blue affiliate's formulary — the Medicare experience differs significantly from the commercial one.
Related Articles
Does BCBS Michigan Cover Contrave? 2026 MI Guide | Curex
BCBS Michigan upheld weight-loss exclusions (DIFS 2025). Contrave is plan-dependent. MI Medicaid favors weight-loss GLP-1s; Contrave varies by PDL.
Read moreDoes BCBS of Illinois Cover Jardiance? 2026
BCBS of Illinois (HCSC) covers Jardiance across commercial, ACA, Medicare, and Medicaid. Metformin-first step is common. 2026 MFP $197 for Medicare.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Ambien? 2026 | Curex
Blue Cross Blue Shield covers generic zolpidem (Tier 1–2); brand Ambien is non-preferred. Quantity limits apply. Verify your specific BCBS plan for 2026.
Read moreDoes BCBS of Texas Cover Ozempic? 2026 Guide | Curex
BCBS Texas (HCSC) covers Ozempic for T2D with PA — not weight loss. HCSC shares PA with BCBS IL. TX Medicaid uses separate Star MCOs. Verify on BCBS TX.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.